Literature DB >> 14636365

Antidepressants in bipolar disorder: the case for caution.

S Nassir Ghaemi1, Douglas J Hsu, Federico Soldani, Frederick K Goodwin.   

Abstract

The 2002 American Psychiatric Association (APA) guidelines for the treatment of bipolar disorder recommended more conservative use of antidepressants. This change in comparison with previous APA guidelines has been criticized, especially from some groups in Europe. The Munich group in particular has published a critique of assumptions underlying the conservative recommendations of the recent APA treatment guidelines. In this paper, we re-examine the argument put forward by the Munich group, and we demonstrate that indeed, conceptually and empirically, there is a strong rationale for a cautious approach to antidepressant use in bipolar disorder, consistent with, and perhaps even more strongly than, the APA guidelines. This rationale is based on support for the following four propositions: (i) The risk of antidepressant induced mood-cycling is high, (ii) Antidepressants have not been shown to definitively prevent completed suicides and reduce mortality, whereas lithium has, (iii) Antidepressants have not been shown to be more effective than mood stabilizers in acute bipolar depression and have been shown to be less effective than mood stabilizers in preventing depressive relapse in bipolar disorder and (iv) Mood stabilizers, especially lithium and lamotrigine, have been shown to be effective in acute and prophylactic treatment of bipolar depressive episodes. We therefore draw three conclusions from this interpretation of the evidence: (i) There are significant risks of mania and long-term worsening of bipolar illness with antidepressants, (ii) Antidepressants should generally be reserved for severe cases of acute bipolar depression and not routinely used in mild to moderate cases and (iii) Antidepressants should be discontinued after recovery from the depressive episode, and maintained only in those who repeatedly relapse after antidepressant discontinuation (a minority we judge to represent only about 15-20% of bipolar depressed patients).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636365     DOI: 10.1046/j.1399-5618.2003.00074.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  56 in total

1.  Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.

Authors:  Jaskaran Singh; Carlos A Zarate; Andrew D Krystal
Journal:  Psychopharmacology (Berl)       Date:  2004-01-14       Impact factor: 4.530

2.  Antidepressants in bipolar disorder.

Authors:  Elisa F Cascade; John Reites; Amir H Kalali; Nassir Ghaemi
Journal:  Psychiatry (Edgmont)       Date:  2007-03

Review 3.  Review of evidence for use of antidepressants in bipolar depression.

Authors:  Shane J McInerney; Sidney H Kennedy
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-16

4.  Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. population.

Authors:  Regina Sala; Benjamin I Goldstein; Carmen Morcillo; Shang-Min Liu; Mariela Castellanos; Carlos Blanco
Journal:  J Psychiatr Res       Date:  2012-04-24       Impact factor: 4.791

5.  Managing bipolar disorder from urgent situations to maintenance therapy.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

6.  CALM: A Mnemonic for Treatment Options for Bipolar Disorder.

Authors:  Roger Sparhawk; S Nassir Ghaemi
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors:  Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

8.  Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids.

Authors:  Francis E Lotrich; Barry Sears; Robert K McNamara
Journal:  J Psychosom Res       Date:  2013-07-26       Impact factor: 3.006

9.  Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

10.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.